 Based on prior published pilot studies, the investigators have initiated a larger, multi-site placebo-controlled clinical trial with Alzheimers disease AD patients and individuals diagnosed with Mild Cognitive Impairment MCI, with the hopes of 1 confirming or denying the above promising clinical findings, and 2 determining whether or not our formulation can delay MCI conversion to AD. 